Trevena - TRVN Stock Forecast, Price & News

0 brokers have issued twelve-month target prices for Trevena's shares. Their TRVN share price forecasts range from $1.50 to $1.50. On average, they anticipate the company's share price to reach $1.50 in the next year. This suggests that the stock has a possible downside of 32.7%.
View analysts price targets for TRVN or view top-rated stocks among Wall Street analysts.

Trevena's stock was trading at $0.5830 at the start of the year. Since then, TRVN stock has increased by 282.5% and is now trading at $2.23.
View the best growth stocks for 2022 here.

Trevena saw a decrease in short interest in November. As of November 15th, there was short interest totaling 166,600 shares, a decrease of 94.8% from the October 31st total of 3,180,000 shares. Based on an average daily trading volume, of 41,200 shares, the short-interest ratio is presently 4.0 days.
View Trevena's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our TRVN earnings forecast.

Trevena, Inc. (NASDAQ:TRVN) released its quarterly earnings data on Monday, November, 15th. The biopharmaceutical company reported ($0.08) EPS for the quarter, beating analysts' consensus estimates of ($0.09) by $0.01. The biopharmaceutical company earned $0.18 million during the quarter, compared to analyst estimates of $1.16 million. During the same quarter in the prior year, the business posted ($0.04) earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other Trevena investors own include Conatus Pharmaceuticals (CNAT), Novavax (NVAX), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Aeterna Zentaris (AEZS), Bionano Genomics (BNGO) and Dynavax Technologies (DVAX).

Trevena trades on the NASDAQ under the ticker symbol "TRVN."

Trevena's stock is owned by a variety of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (15.78%), Ergoteles LLC (9.86%), State Street Corp (8.95%), Virtu Financial LLC (0.17%), Citadel Advisors LLC (0.00%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Barry Shin and Carrie L Bourdow.
View institutional ownership trends.

Shares of TRVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TRVN stock can currently be purchased for approximately $2.23.

Trevena (NASDAQ:TRVN) has a market capitalization of $15.50 million and generates $570,000.00 in revenue each year. The biopharmaceutical company earns $-51,590,000.00 in net income (profit) each year or ($9.00) on an earnings per share basis.

Trevena's mailing address is 955 Chesterbrook Boulevard Suite 110, Chesterbrook PA, 19087. The official website for the company is www.trevena.com. The biopharmaceutical company can be reached via phone at (610) 354-8840 or via email at ir@trevena.com.